- Home
- QLYS vs BLTE Comparison
QLYS vs BLTE Comparison
Compare QLYS & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QLYS | BLTE |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.0B |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | QLYS | BLTE |
|---|---|---|
| Price | $176.96 | $156.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | $133.08 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 680.7K | 143.2K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.99 | N/A |
| EPS | ★ 2.91 | N/A |
| Revenue | ★ $321,607,000.00 | N/A |
| Revenue This Year | $9.97 | N/A |
| Revenue Next Year | $7.15 | $492.11 |
| P/E Ratio | $63.97 | ★ N/A |
| Revenue Growth | ★ 15.32 | N/A |
| 52 Week Low | $74.51 | $63.51 |
| 52 Week High | $201.54 | $200.00 |
Technical Indicators
Market Signals| Indicator | QLYS | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 54.32 | 46.14 |
| Support Level | $128.98 | $146.94 |
| Resistance Level | $199.13 | $161.17 |
| Average True Range (ATR) | 7.61 | 6.65 |
| MACD | -1.82 | -1.60 |
| Stochastic Oscillator | 26.23 | 19.08 |
Price Performance
Historical ComparisonAbout QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.